Unknown

Dataset Information

0

Ceritinib for ALK-Rearrangement-Positive Non-Small Cell Lung Cancer.

ABSTRACT:

SUBMITTER: Nix NM 

PROVIDER: S-EPMC4601895 | biostudies-literature | 2015 Mar-Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Ceritinib for ALK-Rearrangement-Positive Non-Small Cell Lung Cancer.

Nix Nancy M NM   Brown Kaitlyn S KS  

Journal of the advanced practitioner in oncology 20150301 2

Similar Datasets

Unknown Ceritinib in ALK-rearranged non-small-cell lung cancer.
| S-EPMC4079055 | biostudies-literature
Unknown Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib.
| S-EPMC4638315 | biostudies-literature
Unknown The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
| S-EPMC4068971 | biostudies-literature
Unknown Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer.
| S-EPMC5217515 | biostudies-literature
Unknown EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
| S-EPMC2630573 | biostudies-literature
Unknown Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.
| S-EPMC4408973 | biostudies-literature
Unknown New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib.
| S-EPMC4863587 | biostudies-literature
Unknown Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report.
| S-EPMC5690796 | biostudies-literature
Unknown Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials.
| S-EPMC7139871 | biostudies-literature
Unknown Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
| S-EPMC8498851 | biostudies-literature